Q2 2025 Gufic Biosciences Ltd Earnings Call Transcript
Key Points
- The commissioning of the Indore facility marks a transformative milestone, aiming to optimize production capacity and maintain seamless supply chain operations.
- The company is expanding its pipeline with innovative molecules in advanced antibacterial and antifungal classes, addressing therapeutic gaps at competitive prices.
- Gufic Biosciences Ltd (BOM:509079) has received international approvals in countries like Thailand, Sri Lanka, and Lithuania, and won a tender with the UK NHS, enhancing its global presence.
- The Ferticare division is expanding its product pipeline to address the growing need for assisted reproductive technologies in India, with new products like recombinant hormonal products and specialized supplements.
- The Aesthaderm division is expanding its cosmetic portfolio and has positioned its flagship Botulinum Toxin brand, Stunnox, as the second most used in India, indicating strong market acceptance.
- The total revenue for Q2 of '24-'25 decreased compared to the previous year, indicating a decline in sales performance.
- There has been a delay in the Indore facility contributing to revenue, with significant contributions expected only in the next two to three years.
- The company faces challenges with increased debtor days due to direct credit to hospitals, impacting cash flow management.
- The erosion of API pricing from China has affected the revenue from key molecules, contributing to stagnant overall revenues.
- There are operational challenges in transitioning production from Navsari to Indore, although no revenue loss was reported during the transfer process.
Ladies and gentlemen, good day, and welcome to the Q2 and FY25 earnings conference call of Gufic Biosciences Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Ms. Ami Shah, Company Secretary. Thank you, and over to you, ma'am.
Thank you, Sejal. Good evening, everyone. I welcome you all to Gufic Biosciences Limited Earnings Conference Call for the Second Quarter of Financial Year '24-'25. We have with us today Mr. Pranav Choksi, CEO and Director; Mr. Devkinandan Roonghta, CFO; and Mr. Avik Das from Investor Relations team. To give the highlights of the business and financial performance of the company and to take questions, if any.
Before we begin, I would like to state that some of the statements that will be made in today's discussion may be forward-looking in nature. It is subject to unfortunate risks and uncertainties, and the actual results could materially differ. The company undertakes no
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
